ACell's Gentrix Surgical Matrix Provides Exceptional Long-Term Results in Complex Patient Populations for Durable Reinforcement of Ventral Hernias
October 08, 2018 at 12:00 pm
Share
ACell, Inc. announced that impactful data focused on its Gentrix Surgical Matrix family of devices for use in ventral hernia repair was published ahead of print in the peer-reviewed journal Hernia. Gentrix Surgical Matrix devices are a biologically-derived reinforcement material, comprised of ACell's proprietary MatriStem UBM™ (Urinary Bladder Matrix) technology, which may be utilized for a variety of complex hernia and abdominal wall repairs. The study - examining 64 patients with ventral hernias that had been repaired and reinforced with Gentrix Surgical Matrix devices – calculated a recurrence rate of 4.0% and 15.6% at a 24 and 36 month median follow-up time, respectively. As a comparison, several recently published studies with a similar population show recurrence rates of 31.8% at 18 months and 17% at 24 months. In addition, the study includes histological and radiographic evidence demonstrating long-term, robust fascial repairs with remodeling of site-appropriate tissue, as opposed to scar tissue.
ACell Inc is a United States-based company that provides wound management solutions. The Company offers a range of products, including Cytal Burn Matrix, which is a medical device used for the management of second degree burns; Cytal Wound Matrix, which is are used for acute wounds and chronic wounds; Gentrix Surgical Matrix, which is used in a range of surgical procedures, including various types of hernia repair, and MicroMatrix, which is used for acute wounds and chronic wounds. The Company uses MatriStem UBM (Urinary Bladder Matrix) technology for the manufacturing of Gentrix, Cytal, and MicroMatrix product lines.
ACELL, INC. 
